Literature DB >> 8870892

Benchmark analysis of strategies hospitals use to control antimicrobial expenditures.

R P Rifenburg1, J A Paladino, S C Hanson, J A Tuttle, J J Schentag.   

Abstract

Hospital expenditures on antimicrobial drugs, antimicrobial management practices, and the effects of these practices were studied. A survey on institutional budget, size, and staffing; intensive care unit drug costs and use evaluations; and pharmacy expenditures, including antimicrobial costs, for 1993 and 1994 was sent to 122 hospitals. The written survey was followed by telephoned questions regarding each institution's antimicrobial management and expenditures, and any perceived link between the two. Hospitals were grouped by size and type, data were normalized to costs per occupied bed and costs per occupied bed per case mix index, and averages for each size category were calculated for general institutional information and expenses per antimicrobial. Eighty-eight institutions (72%) responded. Although 61% to 74% of the respondents used an antimicrobial formulary to restrict drug choices and control costs, average total antimicrobial expenses increased by more than $300 per occupied bed between 1993 and 1994. Only 7% of the institutions saw decreased costs of $500 or more per occupied bed. The most common reasons for these decreases were restructuring of pricing contracts and implementation of educational programs. The replacement of one formulary alternative with another led to increases in the use of antimicrobials other than the replacement drug and often did not produce savings. The replacement of one formulary antimicrobial with another led more to costshifting than to overall savings.

Mesh:

Substances:

Year:  1996        PMID: 8870892     DOI: 10.1093/ajhp/53.17.2054

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

Review 1.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 2.  The economic potential of dual individualisation methodologies.

Authors:  J A Paladino; G S Zimmer; J J Schentag
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

3.  Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.

Authors:  D J Walters; J S Solomkin; J A Paladino
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 4.  Optimizing antibiotic therapy in the intensive care unit setting.

Authors:  M H Kollef
Journal:  Crit Care       Date:  2001-06-28       Impact factor: 9.097

5.  Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients.

Authors:  K S Kaye; A D Harris; H Gold; Y Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Assessing antibacterial pharmacoeconomics in the intensive care unit.

Authors:  M C Birmingham; J M Hassett; J J Schentag; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

7.  A permission system for carbapenem use reduced incidence of drug-resistant bacteria and cost of antimicrobials at a general hospital in Japan.

Authors:  Yoshiaki Ikeda; Takayoshi Mamiya; Hideki Nishiyama; Shiho Narusawa; Takenao Koseki; Akihiro Mouri; Toshitaka Nabeshima
Journal:  Nagoya J Med Sci       Date:  2012-02       Impact factor: 1.131

8.  Surgeon-led initiatives cut costs and enhance the quality of endoscopic and laparoscopic procedures.

Authors:  Jeff W Allen; Thomas X Hahm; Hiram C Polk
Journal:  JSLS       Date:  2003 Jul-Sep       Impact factor: 2.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.